Centessa Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:CNTA)

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) saw some unusual options trading on Wednesday. Investors bought 10,659 put options on the company. This represents an increase of 1,668% compared to the typical volume of 603 put options.

Centessa Pharmaceuticals News Roundup

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to acquire Centessa in a deal worth up to $7.8 billion (initial $38.00/share cash plus contingent value rights), which creates a takeover premium and is the primary driver of the stock’s upward move. Eli Lilly to buy Centessa Pharma
• Positive Sentiment: Leerink Partners reaffirmed a “market perform” rating and raised its price target to $40.00, a small upward revision that supports the view the deal price is appropriate. Leerink raises price target
• Neutral Sentiment: Unusual options activity: earlier spikes in call buying and, more recently, a large surge in put purchases (10,659 puts) signal mixed positioning—some traders betting on deal completion/arb, others hedging or speculating on downside. (No single article link)
• Negative Sentiment: Multiple brokerages downgraded CNTA (Needham, Wolfe Research, Stephens), citing valuation or deal-related uncertainty — analyst downgrades can weigh on momentum despite the takeover premium. Needham downgrades
• Negative Sentiment: Several law firms and shareholder groups have announced investigations into whether the sale process and price are fair (Monteverde, Kahn Swick & Foti, Ademi, Halper Sadeh). Potential litigation or challenges to the transaction could delay closing or pressure the spread between market price and deal consideration. Shareholder investigation announced
• Negative Sentiment: Recent quarterly results missed EPS estimates (reported ($0.48) vs. consensus ($0.38)), underscoring ongoing clinical and execution risks outside the transaction context. Centessa earnings miss

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Iqbal J. Hussain sold 38,951 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the transaction, the insider owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. This trade represents a 40.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Gregory M. Weinhoff sold 73,196 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the transaction, the insider directly owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 349,073 shares of company stock valued at $9,429,412 in the last three months. 7.09% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals in the fourth quarter valued at $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $36,000. T. Rowe Price Investment Management Inc. lifted its holdings in Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after buying an additional 1,516 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after buying an additional 1,008 shares during the last quarter. Finally, Knott David M Jr acquired a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth about $100,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CNTA. Wolfe Research lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a report on Tuesday. Chardan Capital restated a “buy” rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. Leerink Partners reaffirmed a “market perform” rating and set a $40.00 price objective (up from $36.00) on shares of Centessa Pharmaceuticals in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. Finally, TD Cowen reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.00.

Centessa Pharmaceuticals Stock Up 0.4%

CNTA stock opened at $39.86 on Thursday. The company’s 50 day moving average price is $26.62 and its 200 day moving average price is $25.35. The firm has a market capitalization of $5.82 billion, a price-to-earnings ratio of -21.78 and a beta of 1.25. Centessa Pharmaceuticals has a fifty-two week low of $9.60 and a fifty-two week high of $40.26. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Monday, April 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). On average, equities research analysts anticipate that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.